Cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer.
A Nordic investigator-initiated randomised study.
Adding cetuximab to first-line FOLFIRI improves outcome in RAS and BRAF wild-type metastatic colorectal cancer (mCRC).
Triplet chemotherapy improves efficacy but with increased toxicity.
We assumed that alternating FOLFIRI/FOLFOX maintain efficacy of triplet therapy but with lower toxicity.
Description of the cohort
Histologically verified adenocarcinoma in colon or rectum.
At least 1 measurable metastasis according to RECIST-criteria (version 1.1).
KRAS-, NRAS- og BRAF-status:
Tumor tissue (primary or metastasis) RAS and BRAF wildtype.
Age > 18 years
WHO performance status ≤ 1; life expectancy > 3 months.
Data and biological material
Adverse events, treatment, demography, performance status, response rate, blood, tumor tissue, quality of life.
Collaborating researchers and departments
GCP Unit, Odense University Hospital
Department of Oncology, Uppsala University Hospital
Department of Oncology, Haukeland University Hospital